Abstract: The present invention is directed to cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: Disclosed is a computerized method and system for estimating treatment costs for a health care product and/or service for a health care patient. The estimate of health care costs is calculated before the patient is discharged from the facility providing the health care product or service. The estimate of health care costs may also be performed prior to any treatment or admission to the health care facility of the health care patient. The estimate of treatment costs may include a patient payable amount that estimates the cost of the health care product/service that will be the patient's responsibility. The health care patient may be billed for the health care product or service prior to discharging the health care patient and/or prior to providing the health care product or service to the health care patient.

Abstract: Disclosed is a computerized method and system for estimating treatment costs for a health care product and/or service for a health care patient. The estimate of health care costs is calculated before the patient is discharged from the facility providing the health care product or service. The estimate of health care costs may also be performed prior to any treatment or admission to the health care facility of the health care patient. The estimate of treatment costs may include a patient payable amount that estimates the cost of the health care product/service that will be the patient's responsibility. The health care patient may be billed for the health care product or service prior to discharging the health care patient and/or prior to providing the health care product or service to the health care patient.

Abstract: A coating composition for a particulate filler comprising an organic oligomer containing a plurality of oxy groups, less than 15% of which are comprised in hydroxy groups, organic oligomer components thereof, fillers coated with the coating compositions, organic polymer matrices filled with a dispersion of the coated filler, and processes for the preparation of the oligomer components, the coating compositions, the coated fillers and the filled matrices, and precursors of the coating compositions.

Abstract: A catalyst bed comprising synthetic inorganic polycrystalline fibres, especially alumina or zirconia, having a BET surface area of 5 to 200 m.sup.2 /g and a bulk density of 0.01 to 0.2 g/cc used to support 0.01% to 0.5% by weight of a Group 8 metal, e.g., platinum; used for the catalytic oxidation of a vaporous fuel such as butane in devices such as flameless heaters for use in caravans, hatcheries, greenhouses, etc.